Exelon Transdermal Patches

Product Information *

  • Company:

    Novartis Ireland Limited
  • Status:

    No Recent Update
  • Active Ingredients :

    *Additional information is available upon request

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 12 October 2020

File name

Exelon Patches PF 20-0088 BRAIN REGPIL April 2020_Clean_1602511638.pdf

Reasons for updating

  • Change to name of manufacturer

Updated on 10 December 2019

File name

Exelon Patches REGPIL PF 18-0110 April 2018 IPHA_1575979930.pdf

Reasons for updating

  • Improved presentation of PIL

Updated on 20 November 2019

File name

Exelon Patches REGSPC PF 19-0248 Oct 2019_Clean_1574262922.pdf

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - Marketing authorisation number(s)

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 08 April 2019

File name

Exelon Patches REGSPC May 2018_IPHA_1554729460.pdf

Reasons for updating

  • File format updated to PDF

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 20 September 2018

File name

Exelon Patches 6513945_R91_p1_LFT_X-4 RA reviewed 14.08.2018 IPHA_1537455209.pdf

Reasons for updating

  • New PIL for new product

Updated on 21 May 2018

File name

Exelon Patches REGSPC May 2018_Clean.docx

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Address change due to BREXIT

Updated on 06 March 2018

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 06 March 2018

Reasons for updating

  • Improved presentation of SPC
  • Change from individual to joint SPC

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SmPCs changed from individual to joint, some typographical changes have been made

Updated on 19 May 2016

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to MA holder contact details

Updated on 12 January 2016

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 03 September 2015

Reasons for updating

  • Change to MA holder contact details

Updated on 09 December 2014

Reasons for updating

  • Change of manufacturer

Updated on 29 November 2013

Reasons for updating

  • Change of manufacturer

Updated on 30 August 2013

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 31 August 2012

Reasons for updating

  • Addition of joint PIL covering all presentations

Updated on 14 April 2009

Reasons for updating

  • Change to drug interactions
  • PIL retired pending re-submission

Updated on 06 November 2008

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation
  • Joint SPC superseded by SPCs for individual presentations

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

date of renewal has been amended

Updated on 21 October 2008

Reasons for updating

  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.5 The following statement has been added " Caution is recommended when selecting anaesthetic agents. Possible dosage adjustments or temporarily stopping treatment can be considered if needed"
4.7 Inclusion of the following statement: "As a consequence, rivastigmine has minor or moderate influenses on the ability to drive and use machines".

Updated on 03 September 2008

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 Changes made to Sections 4.5, 4.7 and Section 10.

Updated on 14 May 2008

Reasons for updating

  • New PIL for new product

Updated on 07 January 2008

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)